Literature DB >> 8287759

Utility of BER-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocytochemical study of 232 cases.

A A Diaz-Arias1, T S Loy, J T Bickel, R K Chapman.   

Abstract

The usefulness of a new commercially available monoclonal antibody (MoAb) BER-EP4 was evaluated. This MoAb is directed against a cell surface glycoprotein reported to be present in most epithelial cells and epithelial tumors but not in mesothelial cells. Cell block sections from 103 adenocarcinomatous and 129 benign effusions were studied. Positive staining was seen in 85 of the 103 (83%) malignant effusions. Immunoreactivity was seen in 73-93% of adenocarcinomas from the ovary, gastrointestinal tract, lung, and breast. Mesothelial cells from 3 of the 129 (2%) benign effusions showed positive staining. It is concluded that immunocytochemical staining with MoAb BER-EP4 is a sensitive and specific aid in distinguishing reactive mesothelial cells from adenocarcinoma cells in body fluids.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8287759     DOI： 10.1002/dc.2840090509

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN： 1097-0339            Impact factor:   1.582


  17 in total

1.  Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings.

Authors:  B Risberg; B Davidson; H P Dong; J M Nesland; A Berner
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

2.  High expression of epithelial cellular adhesion molecule in peritoneal metastasis of gastric cancer.

Authors:  Motohiro Imano; Tatsuki Itoh; Takao Satou; Atsushi Yasuda; Kohei Nishiki; Hiroaki Kato; Osamu Shiraishi; Ying-Feng Peng; Masayuki Shinkai; Masahiro Tsubaki; Takushi Yasuda; Haruhiko Imamoto; Shozo Nishida; Yoshifumi Takeyama; Hiroshi Furkawa; Kiyokata Okuno; Hitoshi Shiozaki
Journal:  Target Oncol       Date:  2012-11-17       Impact factor: 4.493

3.  Immunity and immune suppression in human ovarian cancer.

Authors:  Claudia C Preston; Ellen L Goode; Lynn C Hartmann; Kimberly R Kalli; Keith L Knutson
Journal:  Immunotherapy       Date:  2011-04       Impact factor: 4.196

4.  Morphological and immunohistochemical characterization of isolated tumor cells by p53 status in gastrointestinal tumors.

Authors:  C Milsmann; L Füzesi; E Heinmöller; P Krause; C Werner; H Becker; O Horstmann
Journal:  Langenbecks Arch Surg       Date:  2007-09-18       Impact factor: 3.445

5.  FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.

Authors:  Richard E Francis; Stephen S Myatt; Janna Krol; Johan Hartman; Barrie Peck; Ursula B McGovern; Jun Wang; Stephanie K Guest; Aleksandra Filipovic; Ondrej Gojis; Carlo Palmieri; David Peston; Sami Shousha; Qunyan Yu; Piotr Sicinski; R Charles Coombes; Eric W-F Lam
Journal:  Int J Oncol       Date:  2009-07       Impact factor: 5.650

6.  FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.

Authors:  J Millour; D Constantinidou; A V Stavropoulou; M S C Wilson; S S Myatt; J M-M Kwok; K Sivanandan; R C Coombes; R H Medema; J Hartman; A E Lykkesfeldt; E W-F Lam
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

7.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Authors:  Markus M Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O Kolesnik; Vladimir V Ivanchenko; Alexander S Dudnichenko; Birute Aleknaviciene; Arturas Razbadauskas; Martin Gore; Elena Ganea-Motan; Tudor Ciuleanu; Pauline Wimberger; Alexander Schmittel; Barbara Schmalfeldt; Alexander Burges; Carsten Bokemeyer; Horst Lindhofer; Angelika Lahr; Simon L Parsons
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396

8.  Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients.

Authors:  Peter Ruf; Michael Kluge; Michael Jäger; Alexander Burges; Constantin Volovat; Markus Maria Heiss; Jürgen Hess; Pauline Wimberger; Birgit Brandt; Horst Lindhofer
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

9.  Significance of a galactose specific plant lectin for the differential diagnosis of adenocarcinoma cells in effusion.

Authors:  K Sujathan; K Jayasree; P Remani
Journal:  J Cytol       Date:  2009-10       Impact factor: 1.000

10.  Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab).

Authors:  Diane Seimetz
Journal:  J Cancer       Date:  2011-05-25       Impact factor: 4.207
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.